Compare Kimberly Clark Corp (KMB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kimberly Clark Corp trades at $99.99 (market cap $32.69B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Kimberly Clark Corp is far larger — about 4.3× Spyre Therapeutics Inc. Common Stock's market cap, and Kimberly Clark Corp pays a 5.21% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 94 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KMB | SYRE | |
|---|---|---|
Market Cap | $32.69B | $7.52B |
Volume | 6,331,515 | 1,441,031 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $108.92 |
52-Week Low | $93.05 | $22.18 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $38.25B | $6.52B |
Dividend Yield | 5.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $99.41, up 0.65% on the day, showing modest recovery after recent declines. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while fundamentals reveal mixed results with Q2 2026 earnings miss but strong profitability margins. Recent executive transitions and the pending Kenvue acquisition dominate news flow, creating uncertainty around the company's strategic direction and cash flow sustainability.
KMB presents a complex investment case with a 5.16% dividend yield and 54-year dividend growth streak offset by acquisition risks and cash flow concerns. Analyst consensus at $117.25 suggests 18% upside potential, but the stock requires careful monitoring of integration execution and dividend coverage metrics amid changing leadership.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
